Boehringer Ingelheim has announced the implementation of a flexible setup and operational approach for disposable technologies in the manufacturing of biopharmaceutical products.

Thanks to this new arrangement, different single-use systems can be operated in the same facility and by the same experts, regardless of which system was originally selected by customers.

Users of the company's BioXcellence service can now benefit from an unprecedented level of flexibility, reliable and efficient project transfers, and greater ease in outsourcing concepts.

This new development is based on years of experience gathered by Boehringer Ingelheim from different single-use systems.

Hitto Kaufmann, German vice-president for process science at Boehringer Ingelheim Biopharmaceuticals, said: "This platform will be established globally in Boehringer Ingelheim's mammalian facilities and will support clients globally with the same technology as well as quality standards."

This comes after the company announced a new manufacturing agreement with fellow pharmaceutical firm Servier for the novel antibody gevokizumab last month.